SCHEMBL4288098

SCHEMBL4288098

Cc1cc(C(=O)Nc2cc(Oc3ccc(N)nc3)ccc2Cl)n(C)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.53
CDK8 P49336 11/20 0.47
PDGFRB P09619 2/20 0.44
PDGFRA P16234 2/20 0.44
FLT1 P17948 2/20 0.44
AURKA O14965 1/20 0.44
KIT P10721 1/20 0.44
FGFR1 P11362 1/20 0.44
ABL1 P00519 1/20 0.42
CSF1R P07333 1/20 0.42
YES1 P07947 1/20 0.42
RET P07949 1/20 0.42
BCR P11274 1/20 0.42
FLT4 P35916 1/20 0.42
ABL2 P42684 1/20 0.42
DDR1 Q08345 1/20 0.42
DDR2 Q16832 1/20 0.42
AAK1 Q2M2I8 1/20 0.42
Q6ZSR9 Q6ZSR9 1/20 0.42
NEK1 Q96PY6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293238 0.90 KDR (0.55) KDRCDK8PDGFRBPDGFRAFLT1
SCHEMBL3670060 0.88 KDR (0.56) KDRCDK8PDGFRBPDGFRAFLT1
SCHEMBL3677095 0.83 KDR (0.55) KDRCDK8PDGFRBFLT1AURKA
SCHEMBL3673895 0.83 CDK8 (0.62) KDRCDK8PDGFRBFLT1AURKA
SCHEMBL4280567 0.82 KDR (0.61) KDRPDGFRBPDGFRAFLT1AURKA
SCHEMBL3677709 0.80 KDR (0.48) KDRPDGFRBPDGFRAFLT1AURKA
SCHEMBL3637169 0.80 CDK8 (0.58) CDK8
SCHEMBL2516024 0.76 KDR (0.48) KDRPDE10A
SCHEMBL13636123 0.75 CDK8 (0.52) CDK8
SCHEMBL3667721 0.74 KDR (0.54) KDRPDGFRBPDGFRAFLT1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162445-B1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-11-27 EP disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX KDR 2311/4885CDK8 2998/4885PDGFRB 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.